Abstract
Technological progress in the field of high-throughput technology and the scientific advances in molecular screening have set the ground in the last decades for targeted therapy approaches and precision medicine (PM) in oncology. The utility of molecular profiling in cancer for treatment decision still needs to be proven in well-designed prospective randomized trials, the results of which will be decisive in showing whether or not targeted therapy based on molecular profiling can actually be translated into benefit for patients. For a successful transition toward PM in oncology, several challenges including study designs and biomarkers validation, tissue sampling and tumor heterogeneity, standardization of molecular screening techniques, and bioinformatics in the era of continuous technological progress in addition to financial, regulatory, and ethical aspects need to be addressed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892
Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723
Hudson TJ et al (2010) International Cancer Genome Consortium. International network of cancer genome projects. Nature 464(7291):993–998. Erratum in: Nature 465(7300):966
Jakobsen JN, Sørensen JB (2012) Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemother Pharmacol 69(2):289–299
Le Tourneau C, Paoletti X, Servant N et al (2014) Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer 111(1):17–24
Lebofsky R, Decraene C, Bernard V et al (2015) Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 9(4):783–790. doi:10.1016/j.molonc.2014.12.003
McShane LM, Cavenagh MM, Lively TG et al (2013) Criteria for the use of omics-based predictors in clinical trials. Nature 502(7471):317–320
Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature 501(7467):328–337
Sandoval J, Esteller M (2012) Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 22(1):50–55
Servant N, Roméjon J, Gestraud P, La Rosa P, Lucotte G, Lair S, Bernard V, Zeitouni B, Coffin F, Jules-Clément G, Yvon F, Lermine A, Poullet P, Liva S, Pook S, Popova T, Barette C, Prud’homme F, Dick JG, Kamal M, Le Tourneau C, Barillot E, (2014) Hupé P.Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial. Front Genet. 30;5:152. doi:10.3389/fgene.2014.00152. eCollection 2014. Review.
Simon R, Roychowdhury S (2013) Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 12(5):358–369
Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454
Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030
Turner NC, Reis-Filho JS (2012) Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13(4):e178–e185
Vakiani E, Janakiraman M, Shen R et al (2012) Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 30(24):2956–2962
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Kamal, M. (2015). Challenges for the Clinical Implementation of Precision Medicine Trials. In: Le Tourneau, C., Kamal, M. (eds) Pan-cancer Integrative Molecular Portrait Towards a New Paradigm in Precision Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-22189-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-22189-2_9
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22188-5
Online ISBN: 978-3-319-22189-2
eBook Packages: MedicineMedicine (R0)